Occident leads CHF 5.1m series-A for Hemotune

Hemotune plans to use the fresh capital to fund the pre-clinical development of HemoSystem. The participation of GCMS also aims to support the firm's expansion to Asia.

Occident generally writes equity tickets from €500,000 for life sciences investments and from €250,000 for digital startups in Germany and Switzerland. Its recent investments include biotechnology company Tubulis.

Previous funding
In July 2020, EIT Health invested €500,000 in Hemotune. The company has previously received grants from the EU Executive Agency for SMEs, and InnoSuisse.

Company
Hemotune has developed a therapeutic blood purification method known as HemoSystem, which it claims delivers higher precision and efficiency than existing technologies. The technology uses nanoengineered beads, mixing these with blood in a machine similar to a dialysis machine. Hemotune was founded in 2017 as a spin-out from ETH Zurich.

People
Occident – Cédric Barra (manager, life sciences).
Zürcher Kantonalbank – Daniel Schoch (head of startup finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Switzerland